

**AMENDMENTS TO THE SPECIFICATION:**

On page 2, please amend paragraph [007] as shown below:

The documents EP-A 075 436, US 4,734,415 and US 4,353,905 describe pyridazinone derivatives as antihypertensive agents and as agents which increase cardiac contractibility. These pyridazinone derivatives have a phenyl residue at position 6 of the pyridazinone cycle, said phenyl residue is additionally substituted with a heterocycle containing at least one nitrogen atom. Whereas the pyridazinone derivatives described in the documents EP-A 075 436 and US 4,353,905 do not have a substituent at position 4 of the pyridazinone cycle, those disclosed in US 4,734,415 may have an amido group substituted with lower alkyl at this position. Compounds as such, explicitly disclosed by US ~~4,743,415~~ 4,734,415, are not a subject of the present invention.